Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund Highlights: Bill Ackman, Philip Falcone & Paul Singer

Page 1 of 2

Allergan Poison Pill Won’t Be Triggered by Pershing Call (Bloomberg)
Allergan, Inc. (NYSE:AGN) agreed with Pershing Square Capital Management LP that a call for a special shareholder meeting to replace part of the drugmaker’s board won’t trigger a “poison pill” takeover defense. Pershing Square, the hedge fund run by investor Bill Ackman, brought the lawsuit as part of its plan with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to take over Irvine, California-based Allergan, the maker of the Botox wrinkle treatment. Allergan has rejected Valeant’s $54.2 billion offer as inadequate.

Can hedge funds beat the market

New LightSquared Reorganization Plan Includes Cerberus (Wall Street Journal)
Philip Falcone‘s LightSquared wireless venture has a new reorganization plan tentatively in place that includes Cerberus Capital Management LP, according to a person familiar with the negotiations. In addition, the plan doesn’t include LightSquared’s largest secured lender, DISH Network Corp (NASDAQ:DISH). Chairman Charlie Ergen, according to a filing made Friday by the court-appointed mediator, U.S. Bankruptcy Judge Robert Drain. The presence of Cerberus in the negotiations comes as a surprise. Mr. Falcone, who controls most of LightSquared’s equity through his Harbinger Capital Partners hedge fund firm, had testified in bankruptcy court earlier this year that he didn’t want to work with Cerberus when he was pursuing a restructuring plan.

Hedge funds enter market in droves (Business Standard)
Hedge funds, it seems, are making a beeline to enter the Indian stock market. In the past month, big names like Brevan HowardHudson Bay Capital ManagementBalyasny Asset Management, Treeline Investment Management, Segantii Capital Management, Indus Capital and Myraid Capital Management have entered the market. These funds have participated in the qualified institutional placement of Ashok Leyland and others. Sources said the new foreign portfolio investment guidelines of the Securities and Exchange Board of India are encouraging many of these new entrants because of the lower cost involved by listing with the custodians directly.

Same-Sex Marriage Group Key in Rep. Hanna’s GOP Primary Win (Newsmax.com)
A super PAC formed by multimillionaire same-sex marriage advocate Paul Singer played a key role in helping New York Rep. Richard Hanna win his Republican primary this week over conservative state Assemblywoman Claudia Tenney. American Unity PAC, which was established in 2012, spent $500,000 on television and radio ads supporting the two-term Hanna over Tenney, who got support later in the campaign from the tea party and other conservatives, Time magazine reports. Outside groups poured as much as $700,000 into the race.

Juice Press shoots off on vegan vector with ProViotic (New York Post )
Juice Press believes its newest product line will exceed the expectations of even the city’s biggest juice snobs. The chain is pitching ProViotic, a vegan-based probiotic product line derived from bacterial strains that are said to be pristine. The bacteria is found in the European snowdrop flower grown in the mountains of Bulgaria and cultivated in fresh green juice. Michael Karsch, founder of hedge fund Karsch Capital Management and the lead investor in Juice Press, tells Side Dish he learned about it from a Bulgarian business associate.

Miami: Who’s buying it up? (CNBC.com)

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!